University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Clinical Pathology
  • Clinical Pathology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Clinical Pathology
  • Clinical Pathology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs

    Thumbnail
    Download
    Published version (1.788Mb)

    Citations
    Scopus
    Web of Science
    Altmetric
    14
    16
    Author
    Macdonald, J; Henri, J; Roy, K; Hays, E; Bauer, M; Veedu, RN; Pouliot, N; Shigdar, S
    Date
    2018-01-01
    Source Title
    Cancers
    Publisher
    MDPI
    University of Melbourne Author/s
    Pouliot, Normand
    Affiliation
    Clinical Pathology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Macdonald, J., Henri, J., Roy, K., Hays, E., Bauer, M., Veedu, R. N., Pouliot, N. & Shigdar, S. (2018). EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. CANCERS, 10 (1), https://doi.org/10.3390/cancers10010019.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/255960
    DOI
    10.3390/cancers10010019
    Abstract
    The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45770]
    • Clinical Pathology - Research Publications [385]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors